Mediamedic/LinkedIn
Sep 29, 2025, 16:19
Xue Feng Presented Her Work on AAV Vector–Based Gene Therapy
Mediamedic shared a post on LinkedIn:
“ISEH 2025 | Professor Xue Feng: AAV Gene Therapy Transforming Hemophilia B Treatment in China
At the 54th Annual Scientific Meeting of ISEH in Kumamoto, Japan, Professor Xue Feng (Institute of Hematology & Blood Diseases Hospital, CAMS) presented her work on AAV vector–based gene therapy expressing Factor IX Padua for Hemophilia B.
In an exclusive interview with Oncology Frontier – Hematology Frontier, she shared the science behind this innovative approach, its clinical potential, and the future of gene therapy development in China.”
Stay updated with Hemostasis Today.
-
Mar 10, 2026, 14:33Eugene Tang: A Look at What’s Happening in Life After Stroke Research Across Europe at ELASF 2026
-
Mar 10, 2026, 14:25Ahd Elmahi: Complex Case of Catecholamine-Induced Multiorgan Failure and Arterial Thrombosis in Community-Acquired Pneumonia
-
Mar 10, 2026, 13:36Nirupama Yechoor: How Survivors of Stroke Define Spiritual Wellbeing in Recovery
-
Mar 10, 2026, 13:17Jeannie Devereaux: A Novel Technique for Precise High-Dose PRP Injection in Hip Labral Tear
-
Mar 10, 2026, 13:13Wolfgang Miesbach: Highlighting a Critical and Overlooked Dimension of Rare Bleeding Disorders in Women at EAHAD 2026
-
Mar 10, 2026, 13:08Michael Ertl: Honoured To Be Elected Fellow of the European Stroke Organisation
-
Mar 10, 2026, 13:00Nita Radhakrishnan: Benchmarking Hemophilia Care Across Global Income Settings Using Data from India
-
Mar 10, 2026, 12:59Hisam Siddiqi: Night Sweats Are Not Always a Hematological Plot Twist
-
Mar 10, 2026, 12:54Tzu-Fei Wang: Reassuring Real-World Data for Clinicians to Guide Anticoagulation in Prostate Cancer